Derek Maetzold Sells 2,678 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 2,678 shares of Castle Biosciences stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $38.09, for a total transaction of $102,005.02. Following the completion of the sale, the insider owned 30,852 shares of the company’s stock, valued at $1,175,152.68. This trade represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Castle Biosciences Stock Performance

Castle Biosciences stock traded up $0.54 during mid-day trading on Wednesday, reaching $40.61. 274,232 shares of the company traded hands, compared to its average volume of 398,331. The firm’s fifty day moving average is $36.73 and its two-hundred day moving average is $26.50. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -90.24 and a beta of 1.06. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $42.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The firm had revenue of $80.55 million for the quarter, compared to analyst estimates of $71.06 million. On average, equities research analysts expect that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Institutional Trading of Castle Biosciences

A number of institutional investors have recently made changes to their positions in CSTL. Schroder Investment Management Group lifted its holdings in Castle Biosciences by 8.6% in the 2nd quarter. Schroder Investment Management Group now owns 648,572 shares of the company’s stock valued at $13,198,000 after purchasing an additional 51,483 shares in the last quarter. Advisors Capital Management LLC raised its position in shares of Castle Biosciences by 21.9% in the second quarter. Advisors Capital Management LLC now owns 245,867 shares of the company’s stock valued at $5,021,000 after buying an additional 44,180 shares during the last quarter. Squarepoint Ops LLC lifted its stake in Castle Biosciences by 29.1% in the 2nd quarter. Squarepoint Ops LLC now owns 125,719 shares of the company’s stock worth $2,567,000 after purchasing an additional 28,359 shares in the last quarter. Caxton Associates LLP acquired a new position in Castle Biosciences during the first quarter worth $329,000. Finally, Geode Capital Management LLC grew its holdings in shares of Castle Biosciences by 6.2% in the second quarter. Geode Capital Management LLC now owns 689,926 shares of the company’s stock valued at $14,090,000 after purchasing an additional 40,073 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. Guggenheim upped their price objective on shares of Castle Biosciences from $30.00 to $43.00 and gave the company a “buy” rating in a report on Monday. Zacks Research lowered shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Friday, January 2nd. Canaccord Genuity Group raised their target price on Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Finally, Robert W. Baird increased their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.17.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.